FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Stem cell research & therapy2020; 11(1); 187; doi: 10.1186/s13287-020-01706-7

Mass spectrometric analysis of the in vitro secretome from equine bone marrow-derived mesenchymal stromal cells to assess the effect of chondrogenic differentiation on response to interleukin-1β treatment.

Abstract: Similar to humans, the horse is a long-lived, athletic species. The use of mesenchymal stromal cells (MSCs) is a relatively new frontier, but has been used with promising results in treating joint diseases, e.g., osteoarthritis. It is believed that MSCs exert their main therapeutic effects through secreted trophic biomolecules. Therefore, it has been increasingly important to characterize the MSC secretome. It has been shown that the effect of the MSCs is strongly influenced by the environment in the host compartment, and it is a crucial issue when considering MSC therapy. The aim of this study was to investigate differences in the in vitro secreted protein profile between naïve and chondrogenic differentiating bone marrow-derived (BM)-MSCs when exposed to an inflammatory environment. Equine BM-MSCs were divided into a naïve group and a chondrogenic group. Cells were treated with normal expansion media or chondrogenic media. Cells were treated with IL-1β for a period of 5 days (stimulation), followed by 5 days without IL-1β (recovery). Media were collected after 48 h and 10 days. The secretomes were digested and analyzed by nanoLC-MS/MS to unravel the orchestration of proteins. The inflammatory proteins IL6, CXCL1, CXCL6, CCL7, SEMA7A, SAA, and haptoglobin were identified in the secretome after 48 h from all cells stimulated with IL-1β. CXCL8, OSM, TGF-β1, the angiogenic proteins VCAM1, ICAM1, VEGFA, and VEGFC, the proteases MMP1 and MMP3, and the protease inhibitor TIMP3 were among the proteins only identified in the secretome after 48 h from cells cultured in normal expansion media. After 10-day incubation, the proteins CXCL1, CXCL6, and CCL7 were still identified in the secretome from BM-MSCs stimulated with IL-1β, but the essential inducer of inflammation, IL6, was only identified in the secretome from cells cultured in normal expansion media. The findings in this study indicate that naïve BM-MSCs have a more extensive inflammatory response at 48 h to stimulation with IL-1β compared to BM-MSCs undergoing chondrogenic differentiation. This extensive inflammatory response decreased after 5 days without IL-1β (day 10), but a difference in composition of the secretome between naïve and chondrogenic BM-MSCs was still evident.
Get Full Text
Publication Date: 2020-05-20 PubMed ID: 32434555PubMed Central: PMC7238576DOI: 10.1186/s13287-020-01706-7Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research examines the differences in protein secretion profiles between undifferentiated (naïve) and chondrogenic differentiating bone marrow-derived mesenchymal stromal cells (BM-MSCs) of horses when exposed to an inflammatory environment. The findings suggest that naïve BM-MSCs have a stronger inflammatory response to stimulation with the inflammatory protein IL-1β compared to those undergoing chondrogenic differentiation, which could have implications for MSC therapy.

Objective of the Study

  • The aim of this study was to scrutinize difference of the secreted protein profile in the naïve and chondrogenic differentiating BM-MSCs when they are exposed to an inflammatory environment. The bone marrow derived mesenchymal stromal cell (MSC) therapy is a newer stream in medicine and is used to treat joint diseases like osteoarthritis. These MSCs mainly work through secreting therapeutic biomolecules, hence understanding their ‘secretome’ has been seen as important.

Methodology

  • Equine BM-MSCs were divided into two groups: a naïve group and a chondrogenic group. The cells were treated with either regular expansion media or chondrogenic media.
  • They were then exposed to inflammatory protein IL-1β for a period of 5 days (stimulation phase) and then kept for another 5 days without IL-1β (recovery phase).
  • After 48 hours and 10 days, the media were collected and analyzed using nanoLC-MS/MS, a highly sensitive technique for identifying and quantifying proteins.

Results

  • The study found a range of inflammatory proteins like IL6, CXCL1, CXCL6, CCL7, SEMA7A, SAA, and haptoglobin in the secretome (the group of proteins secreted by the cells) from all cells treated with IL-1β after 48 hours.
  • Proteins like CXCL8, OSM, TGF-β1, VCAM1, ICAM1, VEGFA, VEGFC, MMP1, MMP3, and TIMP3 were only identified in the secretome after 48 hours from cells cultured in normal expansion media.
  • Even after 10 days of incubation, CXCL1, CXCL6, and CCL7 proteins were still found in the secretome from MSCs stimulated with IL-1β. IL6, an inducer of inflammation, was only identified in the secretome from cells cultured in normal expansion media.
  • The findings suggest that naïve MSCs have a stronger inflammatory response after 48 hours of exposure to IL-1β than those undergoing differentiation. This response decreases after 5 days without IL-1β but a difference can still be observed in the secretome composition of the two groups after 10 days.

Conclusion

  • The results of the study provide valuable insights into the differences in protein secretion profiles between the naïve and chondrogenic differentiating BM-MSCs under an inflammatory environment.
  • The study adds to the growing body of research on the potential therapeutic applications of MSCs, shedding light on their behavior under inflammatory conditions, like those seen in clinical scenarios such as osteoarthritis.

Cite This Article

APA
Bundgaard L, Stensballe A, Elbæk KJ, Berg LC. (2020). Mass spectrometric analysis of the in vitro secretome from equine bone marrow-derived mesenchymal stromal cells to assess the effect of chondrogenic differentiation on response to interleukin-1β treatment. Stem Cell Res Ther, 11(1), 187. https://doi.org/10.1186/s13287-020-01706-7

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 11
Issue: 1
Pages: 187
PII: 187

Researcher Affiliations

Bundgaard, Louise
  • Department of Veterinary Clinical Sciences, University of Copenhagen, Agrovej 8, 2630, Taastrup, Denmark. lb@sund.ku.dk.
Stensballe, Allan
  • Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7E, 9220, Aalborg Ø, Denmark.
Elbæk, Kirstine Juul
  • Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7E, 9220, Aalborg Ø, Denmark.
Berg, Lise Charlotte
  • Department of Veterinary Clinical Sciences, University of Copenhagen, Agrovej 8, 2630, Taastrup, Denmark.

MeSH Terms

  • Animals
  • Bone Marrow
  • Bone Marrow Cells
  • Cell Differentiation
  • Cells, Cultured
  • Horses
  • Interleukin-1beta
  • Mesenchymal Stem Cells
  • Tandem Mass Spectrometry

Conflict of Interest Statement

The authors declare that they have no competing interests.

References

This article includes 54 references
  1. Contino EK. Management and Rehabilitation of Joint Disease in Sport Horses.. Vet Clin North Am Equine Pract 2018 Aug;34(2):345-358.
    pubmed: 29793734doi: 10.1016/j.cveq.2018.04.007google scholar: lookup
  2. McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, Steadman JR. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects.. Arthroscopy 2011 Nov;27(11):1552-61.
    pubmed: 21862278doi: 10.1016/j.arthro.2011.06.002google scholar: lookup
  3. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014 Mar;43(3):255-65.
    pubmed: 24433318doi: 10.1111/j.1532-950X.2014.12100.xgoogle scholar: lookup
  4. Gnecchi M, Danieli P, Malpasso G, Ciuffreda MC. Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair.. Methods Mol Biol 2016;1416:123-46.
    pubmed: 27236669doi: 10.1007/978-1-4939-3584-0_7google scholar: lookup
  5. Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, Kyurkchiev S. Secretion of immunoregulatory cytokines by mesenchymal stem cells.. World J Stem Cells 2014 Nov 26;6(5):552-70.
    pmc: PMC4178255pubmed: 25426252doi: 10.4252/wjsc.v6.i5.552google scholar: lookup
  6. Riis S, Stensballe A, Emmersen J, Pennisi CP, Birkelund S, Zachar V, Fink T. Mass spectrometry analysis of adipose-derived stem cells reveals a significant effect of hypoxia on pathways regulating extracellular matrix.. Stem Cell Res Ther 2016 Apr 14;7(1):52.
    pmc: PMC4831147pubmed: 27075204doi: 10.1186/s13287-016-0310-7google scholar: lookup
  7. Bara JJ, McCarthy HE, Humphrey E, Johnson WE, Roberts S. Bone marrow-derived mesenchymal stem cells become antiangiogenic when chondrogenically or osteogenically differentiated: implications for bone and cartilage tissue engineering.. Tissue Eng Part A 2014 Jan;20(1-2):147-59.
    pubmed: 23895198doi: 10.1089/ten.tea.2013.0196google scholar: lookup
  8. Rocha B, Calamia V, Casas V, Carrascal M, Blanco FJ, Ruiz-Romero C. Secretome analysis of human mesenchymal stem cells undergoing chondrogenic differentiation.. J Proteome Res 2014 Feb 7;13(2):1045-54.
    pubmed: 24400832doi: 10.1021/pr401030ngoogle scholar: lookup
  9. Maffioli E, Nonnis S, Angioni R, Santagata F, Calì B, Zanotti L, Negri A, Viola A, Tedeschi G. Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines.. J Proteomics 2017 Aug 23;166:115-126.
    pubmed: 28739509doi: 10.1016/j.jprot.2017.07.012google scholar: lookup
  10. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling.. Circ Res 2006 Jun 9;98(11):1414-21.
    pubmed: 16690882doi: 10.1161/01.RES.0000225952.61196.39google scholar: lookup
  11. Tögel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury.. Am J Physiol Renal Physiol 2007 May;292(5):F1626-35.
    pubmed: 17213465doi: 10.1152/ajprenal.00339.2006google scholar: lookup
  12. McFarlin K, Gao X, Liu YB, Dulchavsky DS, Kwon D, Arbab AS, Bansal M, Li Y, Chopp M, Dulchavsky SA, Gautam SC. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat.. Wound Repair Regen 2006 Jul-Aug;14(4):471-8.
    pubmed: 16939576doi: 10.1111/j.1743-6109.2006.00153.xgoogle scholar: lookup
  13. Franquesa M, Hoogduijn MJ, Bestard O, Grinyó JM. Immunomodulatory effect of mesenchymal stem cells on B cells.. Front Immunol 2012;3:212.
    pmc: PMC3400888pubmed: 22833744doi: 10.3389/fimmu.2012.00212google scholar: lookup
  14. Klinker MW, Wei CH. Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.. World J Stem Cells 2015 Apr 26;7(3):556-67.
    pmc: PMC4404391pubmed: 25914763doi: 10.4252/wjsc.v7.i3.556google scholar: lookup
  15. Zanotti L, Angioni R, Calì B, Soldani C, Ploia C, Moalli F, Gargesha M, D'Amico G, Elliman S, Tedeschi G, Maffioli E, Negri A, Zacchigna S, Sarukhan A, Stein JV, Viola A. Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1.. Leukemia 2016 May;30(5):1143-54.
    pmc: PMC4858586pubmed: 26898191doi: 10.1038/leu.2016.33google scholar: lookup
  16. Bundgaard L, Stensballe A, Elbæk KJ, Berg LC. Mapping of equine mesenchymal stromal cell surface proteomes for identification of specific markers using proteomics and gene expression analysis: an in vitro cross-sectional study.. Stem Cell Res Ther 2018 Oct 25;9(1):288.
    pmc: PMC6202851pubmed: 30359315doi: 10.1186/s13287-018-1041-8google scholar: lookup
  17. Al Naem M, Bourebaba L, Kucharczyk K, Röcken M, Marycz K. Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders.. Stem Cell Rev Rep 2020 Apr;16(2):301-322.
    pubmed: 31797146doi: 10.1007/s12015-019-09932-0google scholar: lookup
  18. Liu X, Zhang T, Wang R, Shi P, Pan B, Pang X. Insulin-Transferrin-Selenium as a Novel Serum-free Media Supplement for the Culture of Human Amnion Mesenchymal Stem Cells.. Ann Clin Lab Sci 2019 Jan;49(1):63-71.
    pubmed: 30814079
  19. Mainzer C, Barrichello C, Debret R, Remoué N, Sigaudo-Roussel D, Sommer P. Insulin-transferrin-selenium as an alternative to foetal serum for epidermal equivalents.. Int J Cosmet Sci 2014 Oct;36(5):427-35.
    pubmed: 24847782doi: 10.1111/ics.12141google scholar: lookup
  20. Jiang L, He L, Fountoulakis M. Comparison of protein precipitation methods for sample preparation prior to proteomic analysis.. J Chromatogr A 2004 Jan 16;1023(2):317-20.
    pubmed: 14753699doi: 10.1016/j.chroma.2003.10.029google scholar: lookup
  21. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ.. Mol Cell Proteomics 2014 Sep;13(9):2513-26.
    pmc: PMC4159666pubmed: 24942700doi: 10.1074/mcp.M113.031591google scholar: lookup
  22. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible.. Nucleic Acids Res 2017 Jan 4;45(D1):D362-D368.
    pmc: PMC5210637pubmed: 27924014doi: 10.1093/nar/gkw937google scholar: lookup
  23. Vizcaíno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H. 2016 update of the PRIDE database and its related tools.. Nucleic Acids Res 2016 Dec 15;44(22):11033.
    pmc: PMC5159556pubmed: 27683222doi: 10.1093/nar/gkw880google scholar: lookup
  24. Vézina Audette R, Lavoie-Lamoureux A, Lavoie JP, Laverty S. Inflammatory stimuli differentially modulate the transcription of paracrine signaling molecules of equine bone marrow multipotent mesenchymal stromal cells.. Osteoarthritis Cartilage 2013 Aug;21(8):1116-24.
    pubmed: 23685224doi: 10.1016/j.joca.2013.05.004google scholar: lookup
  25. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.. Vet Immunol Immunopathol 2016 Mar;171:57-65.
    pubmed: 26964718doi: 10.1016/j.vetimm.2016.02.007google scholar: lookup
  26. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation.. Signal Transduct Target Ther 2017;2:17023-.
    pmc: PMC5661633pubmed: 29158945doi: 10.1038/sigtrans.2017.23google scholar: lookup
  27. Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade.. Cytokine Growth Factor Rev 2015 Oct;26(5):475-87.
    pubmed: 26189695doi: 10.1016/j.cytogfr.2015.07.004google scholar: lookup
  28. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis.. Semin Immunol 2003 Feb;15(1):15-21.
    pubmed: 12495637doi: 10.1016/s1044-5323(02)00124-0google scholar: lookup
  29. Xie J, Wang H. Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis.. Arthritis Res Ther 2017 Jan 21;19(1):10.
    pmc: PMC5251212pubmed: 28109308doi: 10.1186/s13075-016-1217-5google scholar: lookup
  30. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation.. J Leukoc Biol 1994 Nov;56(5):559-64.
    pubmed: 7964163
  31. Barksby HE, Hui W, Wappler I, Peters HH, Milner JM, Richards CD, Cawston TE, Rowan AD. Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair.. Arthritis Rheum 2006 Feb;54(2):540-50.
    pubmed: 16447230doi: 10.1002/art.21574google scholar: lookup
  32. Malemud CJ. Matrix Metalloproteinases and Synovial Joint Pathology.. Prog Mol Biol Transl Sci 2017;148:305-325.
    pubmed: 28662824doi: 10.1016/bs.pmbts.2017.03.003google scholar: lookup
  33. Finnson KW, Chi Y, Bou-Gharios G, Leask A, Philip A. TGF-b signaling in cartilage homeostasis and osteoarthritis.. Front Biosci (Schol Ed) 2012 Jan 1;4:251-68.
    pubmed: 22202058doi: 10.2741/S266google scholar: lookup
  34. Pober JS. Endothelial activation: intracellular signaling pathways.. Arthritis Res 2002;4 Suppl 3(Suppl 3):S109-16.
    pmc: PMC3240152pubmed: 12110129doi: 10.1186/ar576google scholar: lookup
  35. MacDonald IJ, Liu SC, Su CM, Wang YH, Tsai CH, Tang CH. Implications of Angiogenesis Involvement in Arthritis.. Int J Mol Sci 2018 Jul 10;19(7).
    pmc: PMC6073145pubmed: 29996499doi: 10.3390/ijms19072012google scholar: lookup
  36. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Gosálvez J, Roy R, Zaragoza P, Martín-Burriel I, Rodellar C. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.. Stem Cells Dev 2017 Jan 1;26(1):15-24.
    pubmed: 27712399doi: 10.1089/scd.2016.0209google scholar: lookup
  37. Felka T, Schäfer R, Schewe B, Benz K, Aicher WK. Hypoxia reduces the inhibitory effect of IL-1beta on chondrogenic differentiation of FCS-free expanded MSC.. Osteoarthritis Cartilage 2009 Oct;17(10):1368-76.
    pubmed: 19463979doi: 10.1016/j.joca.2009.04.023google scholar: lookup
  38. Bartucci R, Salvati A, Olinga P, Boersma YL. Vanin 1: Its Physiological Function and Role in Diseases.. Int J Mol Sci 2019 Aug 9;20(16).
    pmc: PMC6719204pubmed: 31404995doi: 10.3390/ijms20163891google scholar: lookup
  39. Zhang Y, Wang T, Cao Y. Osteopontin can decrease the expression of Col-II and COMP in cartilage cells in vitro.. Int J Clin Exp Med 2015;8(2):2254-60.
    pmc: PMC4402806pubmed: 25932159
  40. Cheng C, Gao S, Lei G. Association of osteopontin with osteoarthritis.. Rheumatol Int 2014 Dec;34(12):1627-31.
    pubmed: 24807695doi: 10.1007/s00296-014-3036-9google scholar: lookup
  41. Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH, Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, Balsa A, Kawasaki A, Nicaise P, Amos C, Rodriguez-Rodriguez L, Chiocchia G, Boileau C, Zhang J, Vittecoq O, Barnetche T, Gonzalez Gay MA, Furukawa H, Cantagrel A, Le Loët X, Sumida T, Hurtado-Nedelec M, Richez C, Chollet-Martin S, Schaeverbeke T, Combe B, Khoryati L, Coustet B, El-Benna J, Siminovitch K, Plenge R, Padyukov L, Martin J, Tsuchiya N, Dieudé P. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene.. Ann Rheum Dis 2015 Mar;74(3):e19.
    pubmed: 24448344doi: 10.1136/annrheumdis-2013-204581google scholar: lookup
  42. Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O'Hara R, FitzGerald O, Veale DJ, Fearon U. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway.. Arthritis Rheum 2006 Jan;54(1):105-14.
    pubmed: 16385502doi: 10.1002/art.21518google scholar: lookup
  43. Elshabrawy HA, Volin MV, Essani AB, Chen Z, McInnes IB, Van Raemdonck K, Palasiewicz K, Arami S, Gonzalez M, Ashour HM, Kim SJ, Zhou G, Fox DA, Shahrara S. IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells.. Angiogenesis 2018 May;21(2):215-228.
    pmc: PMC5878720pubmed: 29327326doi: 10.1007/s10456-017-9589-ygoogle scholar: lookup
  44. Acharya C, Yik JH, Kishore A, Van Dinh V, Di Cesare PE, Haudenschild DR. Cartilage oligomeric matrix protein and its binding partners in the cartilage extracellular matrix: interaction, regulation and role in chondrogenesis.. Matrix Biol 2014 Jul;37:102-11.
    pubmed: 24997222doi: 10.1016/j.matbio.2014.06.001google scholar: lookup
  45. Ochi K, Derfoul A, Tuan RS. A predominantly articular cartilage-associated gene, SCRG1, is induced by glucocorticoid and stimulates chondrogenesis in vitro.. Osteoarthritis Cartilage 2006 Jan;14(1):30-8.
    pubmed: 16188469doi: 10.1016/j.joca.2005.07.015google scholar: lookup
  46. Mis EK, Liem KF Jr, Kong Y, Schwartz NB, Domowicz M, Weatherbee SD. Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte maturation and skeletal length.. Dev Biol 2014 Jan 1;385(1):67-82.
    pmc: PMC3895954pubmed: 24161523doi: 10.1016/j.ydbio.2013.10.014google scholar: lookup
  47. Johnson HJ, Rosenberg L, Choi HU, Garza S, Höök M, Neame PJ. Characterization of epiphycan, a small proteoglycan with a leucine-rich repeat core protein.. J Biol Chem 1997 Jul 25;272(30):18709-17.
    pubmed: 9228042doi: 10.1074/jbc.272.30.18709google scholar: lookup
  48. Sugars RV, Olsson ML, Marchner S, Hultenby K, Wendel M. The glycosylation profile of osteoadherin alters during endochondral bone formation.. Bone 2013 Apr;53(2):459-67.
    pubmed: 23337037doi: 10.1016/j.bone.2013.01.022google scholar: lookup
  49. Nakajima M, Kizawa H, Saitoh M, Kou I, Miyazono K, Ikegawa S. Mechanisms for asporin function and regulation in articular cartilage.. J Biol Chem 2007 Nov 2;282(44):32185-92.
    pubmed: 17827158doi: 10.1074/jbc.M700522200google scholar: lookup
  50. Poole AR, Matsui Y, Hinek A, Lee ER. Cartilage macromolecules and the calcification of cartilage matrix.. Anat Rec 1989 Jun;224(2):167-79.
    pubmed: 2672883doi: 10.1002/ar.1092240207google scholar: lookup
  51. Knudson CB, Knudson W. Cartilage proteoglycans.. Semin Cell Dev Biol 2001 Apr;12(2):69-78.
    pubmed: 11292372doi: 10.1006/scdb.2000.0243google scholar: lookup
  52. Ranera B, Remacha AR, Álvarez-Arguedas S, Castiella T, Vázquez FJ, Romero A, Zaragoza P, Martín-Burriel I, Rodellar C. Expansion under hypoxic conditions enhances the chondrogenic potential of equine bone marrow-derived mesenchymal stem cells.. Vet J 2013 Feb;195(2):248-51.
    pubmed: 22771146doi: 10.1016/j.tvjl.2012.06.008google scholar: lookup
  53. Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components.. Exp Cell Res 2001 Aug 15;268(2):189-200.
    pubmed: 11478845doi: 10.1006/excr.2001.5278google scholar: lookup
  54. Deutsch EW, Lane L, Overall CM, Bandeira N, Baker MS, Pineau C, Moritz RL, Corrales F, Orchard S, Van Eyk JE, Paik YK, Weintraub ST, Vandenbrouck Y, Omenn GS. Human Proteome Project Mass Spectrometry Data Interpretation Guidelines 3.0.. J Proteome Res 2019 Dec 6;18(12):4108-4116.
    pmc: PMC6986310pubmed: 31599596doi: 10.1021/acs.jproteome.9b00542google scholar: lookup

Citations

This article has been cited 15 times.
  1. Liu Q, Li J, Chang J, Guo Y, Wen D. The characteristics and medical applications of antler stem cells. Stem Cell Res Ther 2023 Aug 30;14(1):225.
    doi: 10.1186/s13287-023-03456-8pubmed: 37649124google scholar: lookup
  2. Xue Z, Liao Y, Li Y. Effects of microenvironment and biological behavior on the paracrine function of stem cells. Genes Dis 2024 Jan;11(1):135-147.
    doi: 10.1016/j.gendis.2023.03.013pubmed: 37588208google scholar: lookup
  3. Jammes M, Contentin R, Cassé F, Galéra P. Equine osteoarthritis: Strategies to enhance mesenchymal stromal cell-based acellular therapies. Front Vet Sci 2023;10:1115774.
    doi: 10.3389/fvets.2023.1115774pubmed: 36846261google scholar: lookup
  4. Poplawski P, Alseekh S, Jankowska U, Skupien-Rabian B, Iwanicka-Nowicka R, Kossowska H, Fogtman A, Rybicka B, Bogusławska J, Adamiok-Ostrowska A, Hanusek K, Hanusek J, Koblowska M, Fernie AR, Piekiełko-Witkowska A. Coordinated reprogramming of renal cancer transcriptome, metabolome and secretome associates with immune tumor infiltration. Cancer Cell Int 2023 Jan 5;23(1):2.
    doi: 10.1186/s12935-022-02845-ypubmed: 36604669google scholar: lookup
  5. Bagge J, Berg LC, Janes J, MacLeod JN. Donor age effects on in vitro chondrogenic and osteogenic differentiation performance of equine bone marrow- and adipose tissue-derived mesenchymal stromal cells. BMC Vet Res 2022 Nov 3;18(1):388.
    doi: 10.1186/s12917-022-03475-2pubmed: 36329434google scholar: lookup
  6. Dechêne L, Colin M, Demazy C, Fransolet M, Niesten A, Arnould T, Serteyn D, Dieu M, Renard P. Characterization of the Proteins Secreted by Equine Muscle-Derived Mesenchymal Stem Cells Exposed to Cartilage Explants in Osteoarthritis Model. Stem Cell Rev Rep 2023 Feb;19(2):550-567.
    doi: 10.1007/s12015-022-10463-4pubmed: 36271312google scholar: lookup
  7. Koch DW, Berglund AK, Messenger KM, Gilbertie JM, Ellis IM, Schnabel LV. Interleukin-1β in tendon injury enhances reparative gene and protein expression in mesenchymal stem cells. Front Vet Sci 2022;9:963759.
    doi: 10.3389/fvets.2022.963759pubmed: 36032300google scholar: lookup
  8. Roth SP, Burk J, Brehm W, Troillet A. MSC in Tendon and Joint Disease: The Context-Sensitive Link Between Targets and Therapeutic Mechanisms. Front Bioeng Biotechnol 2022;10:855095.
    doi: 10.3389/fbioe.2022.855095pubmed: 35445006google scholar: lookup
  9. Yue D, Du L, Zhang B, Wu H, Yang Q, Wang M, Pan J. Time-dependently Appeared Microenvironmental Changes and Mechanism after Cartilage or Joint Damage and the Influences on Cartilage Regeneration. Organogenesis 2021 Oct 2;17(3-4):85-99.
    doi: 10.1080/15476278.2021.1991199pubmed: 34806543google scholar: lookup
  10. Mocchi M, Grolli S, Dotti S, Di Silvestre D, Villa R, Berni P, Conti V, Passignani G, Brambilla F, Bue MD, Catenacci L, Sorrenti M, Segale L, Bari E, Mauri P, Torre ML, Perteghella S. Equine Mesenchymal Stem/Stromal Cells Freeze-Dried Secretome (Lyosecretome) for the Treatment of Musculoskeletal Diseases: Production Process Validation and Batch Release Test for Clinical Use. Pharmaceuticals (Basel) 2021 Jun 10;14(6).
    doi: 10.3390/ph14060553pubmed: 34200627google scholar: lookup
  11. Harman RM, Marx C, Van de Walle GR. Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy. Front Cell Dev Biol 2021;9:654885.
    doi: 10.3389/fcell.2021.654885pubmed: 33869217google scholar: lookup
  12. Ribitsch I, Oreff GL, Jenner F. Regenerative Medicine for Equine Musculoskeletal Diseases. Animals (Basel) 2021 Jan 19;11(1).
    doi: 10.3390/ani11010234pubmed: 33477808google scholar: lookup
  13. Chang C, Yan J, Yao Z, Zhang C, Li X, Mao HQ. Effects of Mesenchymal Stem Cell-Derived Paracrine Signals and Their Delivery Strategies. Adv Healthc Mater 2021 Apr;10(7):e2001689.
    doi: 10.1002/adhm.202001689pubmed: 33433956google scholar: lookup
  14. Harman RM, Patel RS, Fan JC, Park JE, Rosenberg BR, Van de Walle GR. Single-cell RNA sequencing of equine mesenchymal stromal cells from primary donor-matched tissue sources reveals functional heterogeneity in immune modulation and cell motility. Stem Cell Res Ther 2020 Dec 4;11(1):524.
    doi: 10.1186/s13287-020-02043-5pubmed: 33276815google scholar: lookup
  15. Bagge J, Mahmood H, Janes J, Vomstein K, Blønd L, Hölmich LR, Freude K, Nehlin JO, Barfod KW, Hölmich P. Chondrogenic and Osteogenic In Vitro Differentiation Performance of Unsorted and Sorted CD34(+), CD146(+), and CD271(+) Stem Cells Derived from Microfragmented Adipose Tissue of Patients with Knee Osteoarthritis. J Clin Med 2025 Feb 11;14(4).
    doi: 10.3390/jcm14041184pubmed: 40004714google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.